Jennison Associates
ACAD icon

Jennison Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Jennison Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-58,139
Closed -$1.36M – 626
2021
Q4 		$1.36M Sell
58,139
-19,501
-25% -$392K ﹤0.01% 579
2021
Q3 		$1.29M Buy
+77,640
New +$1.5M ﹤0.01% 581
2021
Q1 		– Sell
-580,567
Closed -$31M – 664
2020
Q4 		$31M Buy
580,567
+428,136
+281% +$21.3M 0.02% 290
2020
Q3 		$6.29M Buy
152,431
+608
+0.4% +$26.3K 0.01% 419
2020
Q2 		$7.36M Sell
151,823
-15,404
-9% -$739K 0.01% 404
2020
Q1 		$7.07M Buy
167,227
+17,642
+12% +$727K 0.01% 370
2019
Q4 		$6.4M Buy
+149,585
New +$6.51M 0.01% 416
2017
Q1 		– Sell
-1,372,679
Closed -$39.6M – 641
2016
Q4 		$39.6M Buy
+1,372,679
New +$36.3M 0.04% 304
2016
Q2 		– Sell
-58,417
Closed -$1.63M – 632
2016
Q1 		$1.63M Sell
58,417
-534,789
-90% -$11.7M ﹤0.01% 541
2015
Q4 		$21.1M Sell
593,206
-504,158
-46% -$17.8M 0.02% 419
2015
Q3 		$36.3M Sell
1,097,364
-1,423,960
-56% -$59.2M 0.04% 351
2015
Q2 		$106M Buy
2,521,324
+40,103
+2% +$1.55M 0.1% 194
2015
Q1 		$80.9M Sell
2,481,221
-392,795
-14% -$13.5M 0.07% 245
2014
Q4 		$91.3M Sell
2,874,016
-29,473
-1% -$836K 0.09% 223
2014
Q3 		$71.9M Sell
2,903,489
-150,036
-5% -$3.51M 0.07% 257
2014
Q2 		$69M Buy
3,053,525
+4,108
+0.1% +$85.8K 0.06% 275
2014
Q1 		$74.2M Buy
3,049,417
+1,485,866
+95% +$37.6M 0.07% 253
2013
Q4 		$39.1M Buy
1,563,551
+50,359
+3% +$1.19M 0.04% 356
2013
Q3 		$41.6M Sell
1,513,192
-9,822
-0.6% -$205K 0.04% 332
2013
Q2 		$27.6M Buy
+1,523,014
New +$21M 0.03% 387

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates's ACAD Position: Q1 2022 in Review

Jennison Associates sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 58,139 shares — an estimated $1.36M sold.

Jennison Associates first reported a position in ACAD in Q2 2013 and held it in 20 quarters. The position peaked at $106M in Q2 2015. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

  • Jennison Associates reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 58,139 Acadia Pharmaceuticals shares in Q1 2022, an estimated $1.36M.
  • Jennison Associates first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Jennison Associates's Acadia Pharmaceuticals position peaked at $106M in Q2 2015.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.